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Abstract
Exome sequencing of primary tumors identifies complex somatic mutation patterns. Assignment of relevance of
individual somatic mutations is difficult and poses the next challenge for interpretation of next generation sequencing
data. Here we present an approach how exome sequencing in combination with SNP microarray data may identify
targets of chromosomal aberrations in myeloid malignancies. The rationale of this approach is that hotspots of
chromosomal aberrations might also harbor point mutations in the target genes of deletions, gains or uniparental
disomies (UPDs). Chromosome 11 is a frequent target of lesions in myeloid malignancies. Therefore, we studied
chromosome 11 in a total of 813 samples from 773 individual patients with different myeloid malignancies by SNP
microarrays and complemented the data with exome sequencing in selected cases exhibiting chromosome 11
defects. We found gains, losses and UPDs of chromosome 11 in 52 of the 813 samples (6.4%). Chromosome 11q
UPDs frequently associated with mutations of CBL. In one patient the 11qUPD amplified somatic mutations in both
CBL and the DNA repair gene DDB1. A duplication within MLL exon 3 was detected in another patient with 11qUPD.
We identified several common deleted regions (CDR) on chromosome 11. One of the CDRs associated with de novo
acute myeloid leukemia (P=0.013). One patient with a deletion at the LMO2 locus harbored an additional point
mutation on the other allele indicating that LMO2 might be a tumor suppressor frequently targeted by 11p deletions.
Our chromosome-centered analysis indicates that chromosome 11 contains a number of tumor suppressor genes
and that the role of this chromosome in myeloid malignancies is more complex than previously recognized.
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Introduction
Hematological malignancies are broadly categorized into
myeloid and lymphoid malignancies, depending on the
hematopoietic lineage involved. This study focused on myeloid
malignancies, in particular the disease entities acute myeloid
leukemia (AML), chronic myeloid leukemia (CML),
myelodysplastic syndromes (MDS) as well as the three
classical myeloproliferative neoplasms (MPNs) polycythemia
vera (PV), essential thrombocythemia (ET) and primary
myelofibrosis (PMF). MDS and MPN are in most cases stable,
chronic diseases. A fraction of patients, however, develop
signs of disease progression such as myelofibrosis or elevated
numbers of hematopoietic progenitors in peripheral blood
referred to as “accelerated phase”. A transformation to post-
MPN or post-MDS AML marks the final stage of the disease
and is associated with a very bad prognosis [1]. Genetic
aberrations involving chromosome 11 have been widely
reported across all hematological malignancies. Translocations
of chromosome 11q affecting the 11q23 region have been
intensely studied since the late 1970s when the first
translocation between chromosomes 11 and 4 was described
in acute lymphoblastic leukemia (ALL) [2]. In 1991 the gene
that was affected by these translocations on chromosome 11
was identified to be MLL (myeloid/lymphoid or mixed-lineage
leukemia) [3]. These translocations t(4;11) led to the formation
of a fusion gene of MLL and AF4 (ALL1-fused gene from
chromosome 4; current official symbol AFF1) on chromosome
4 [4]. Since then a variety of translocations involving MLL and
more than 60 fusion gene partners have been identified. They
are found both, in ALL and AML with a high prevalence in
infants [5]. In addition to translocations, partial tandem
duplications of MLL have also been described in AML [6,7].
The internal tandem duplications of MLL most often span
between exon 3 and exons 9-11 [8], and show a strong
association with chromosome 11q trisomies [7]. Classical
karyotyping has revealed chromosomal deletions as common
genetic changes in chronic lymphoid leukemia (CLL), AML,
MDS and other hematological malignancies. A frequently
deleted region mapped to 11q23 [9]. In recent years the
upcoming of single nucleotide polymorphism (SNP)
microarrays has allowed the detection of chromosomal gains
and losses at a much higher resolution than with classical
cytogenetics. Acquired copy number neutral loss of
heterozygosity (LOH) associated with uniparental disomies
(UPD), which were previously undetectable by classical
cytogenetics, are now recurrently found in hematological
malignancies. The first large study in AML using SNP
microarrays identified chromosomal aberrations of all three
types across the whole genome [10]. We, alongside others,
reported such studies in the myeloproliferative neoplasms
(MPN) [11-14]. All of these studies observed frequent
aberrations on chromosome 11 including gains, losses and
UPDs. UPDs were shown to somatically amplify mutant alleles
of genes on various chromosomal arms such as 9p (JAK2), 1p
(MPL) or 4q (TET2) [15-23]. On the short arm of chromosome
11, mutant alleles of WT1 were associated with UPDs in AML
[24], while CBL mutations were associated with UPDs on
chromosome 11q in several hematological
malignancies[25-27]. CBL encodes an E3 ubiquitin ligase that
attaches ubiquitin to a number of membrane-associated and
cytosolic proteins (such as Flt3, Kit, Jak2 and Mpl) and targets
them for degradation [28,29]. In this study, we present a
systematic analysis of chromosome 11 in a set of 813 samples
across different myeloid malignancies. We used high resolution
SNP microarrays and whole exome sequencing to identify
novel genetic aberrations of chromosome 11 in myeloid
malignancies. We were able to detect commonly aberrant
regions on this chromosome and to identify potential target
genes of large aberrations.
Results and Discussion
Chromosome 11 aberrations in myeloid malignancies
In order to systematically analyze chromosome 11
aberrations in myeloid malignancies, we combined data from a
total of 813 blood samples that were genotyped at high-
resolution with Affymetrix Genome-Wide Human SNP 6.0
microarrays. This cohort included 180 de novo acute myeloid
leukemia (AML), 62 chronic myeloid leukemia (CML), 101
myelodysplastic syndrome (MDS), 244 polycythemia vera (PV),
118 essential thrombocythemia (ET) and 108 primary
myelofibrosis (PMF) samples (Table 1, Figure 1A). For PV, ET,
PMF and MDS, the majority of samples were in chronic phase
of the disease, some samples were taken when patients
showed signs of disease progression or had transformed to
post-chronic phase AML as outlined in Table 1. Chromosome
11 aberrations were detected in 52 of 813 samples (6.4%)
(Table 1 and Figure 1B). The 52 samples were from 50
patients, for 2 patients we had 2 samples from different disease
stages (Table S1). The samples harbored between 1 to 3
genetic changes on chromosome 11, except for sample 42
which had a complex aberration of chromosome 11 (Table S1).
Excluding sample 42, we detected a total of 30 deletions, 11
gains and 17 UPDs (Figure 2 and Table S1). In MPN,
aberrations of chromosome 11 significantly associate with post-
MPN AML compared to chronic phase MPN (P<0.0001,
Fisher’s exact test, Figure 1B). MPN patients that exhibited
myelofibrosis or were in the accelerated phase of the disease
but had not fully transformed to post-MPN AML (<20% of blasts
in peripheral blood or bone marrow) were regarded as chronic
phase patients in this analysis. This finding indicates that
genes located on chromosome 11 contribute to disease
progression if mutated. Associations of chromosome 11q
losses of heterozygosity with disease progression or poor
prognosis have been described previously in B cell chronic
lymphatic leukemia [30] or neuroblastoma [31]. Abnormalities
of chromosomal band 11q23 were associated with a poor
outcome in infant acute lymphoblastic leukemia (ALL) [32].
CBL is a frequent target of chromosome 11q
aberrations
We found that UPDs of chromosome 11q are the most
recurrent defects in our dataset. A number of studies have
shown that 11q UPDs are associated with mutations of the
CBL gene (ensembl gene ID: ENSG00000110395) [25-27].
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Table 1. Cohort characteristics.
Disease entity Specific diagnosis Total (n)  With chr 11 lesions (n)
MPN Polycythemia vera 177 3
 post-PV MF 48 3
 post-PV AML 19 3
 Essential thrombocythemia 91 2
 post-ET MF 18 1
 post-ET AML 9 1
 Primary Myelofibrosis 85 5
 post-PMF AP 7 0
 post-PMF AML 16 6
MDS MDS (chronic phase) 61 3
 post-MDS AML 40 5
de novo AML de novo AML 180 19
CML CML 62 1
total  813 52
n, number of samples; MPN, myeloproliferative neoplasms; MDS, myelodysplastic
syndrome; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; PV,
polycythemia vera; ET, essential thrombocythemia; PMF, primary myelofibrosis;
MF, myelofibrosis; AP, accelerated phase; chr, chromosome
doi: 10.1371/journal.pone.0077819.t001
Mutations of CBL have been described to cluster within exons
8 and 9 or their exon-intron junctions [25-27]. Therefore, we
sequenced these two exons of CBL in all samples that
harbored chromosomal aberrations overlapping the CBL locus.
Of the 14 patients that had 11q UPDs, we detected SNVs in 9
patients (Table S1). One patient (sample 45) harbored a 6 bp
tandem duplication (Figure 3A). Out of 6 patients that had 11q
gains overlapping CBL, one had a somatic mutation in CBL
(C384Y in sample 44). PCR subcloning revealed that the gain
amplifies the mutant allele (data not shown). No mutations
were detected in the 7 patients with deletions overlapping CBL.
For the patients where we had control tissue available, the
somatic origin of the variants detected in CBL was confirmed
(Table S1). In order to identify mutations in other exons of CBL
or in other genes that potentially associate with 11q aberrations
we performed whole exome sequencing on three samples with
11q uniparental disomies (samples 30, 36 and 50) and two
samples with 11q gains (samples 42 and 43) which did not
have mutations in exons 8 and 9 of CBL. Only one of these
samples (36) showed a mutation in CBL at the 3’ splice site of
exon 7 (Table S1). The variant was somatic and independently
validated by Sanger sequencing.
Figure 1.  Cohort distribution.  A: Distribution of the 813 samples analyzed by Affymetrix microarrays according to diagnosis. B:
Fraction of samples that harbor chromosome 11 aberrations (black bars) for each disease entity in percent. The P-value indicates
an association of chromosome 11 aberrations with disease progression in MPN. MPN, myeloproliferative neoplasm; CML, chronic
myeloid leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome.
doi: 10.1371/journal.pone.0077819.g001
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CBL mutations associate with leukemic transformation
of MPN
As shown in Figure 1B, we associated chromosome 11
defects with leukemic transformation of MPN. In order to test if
CBL mutations distinctly associate with disease progression,
we sequenced CBL exons 8 and 9 in all 44 post-MPN AML
samples and 274 chronic phase MPN samples. CBL mutations
were present in 1.4% of chronic phase and 15.9% of post-MPN
leukemic patients, respectively. Thus, CBL mutations are
significantly associated with post-MPN AML (P=0.0001;
Fisher’s exact test). A particularly interesting case in this set of
patients had two mutations of CBL affecting exon 8 (W408C)
and the 5’ splice site of exon 9 (Figure 3B). Both mutations
were somatic and PCR subcloning revealed that these two
mutations were on independent DNA strands. As all the
bacterial clones analyzed contained only one of the mutations
and no clones with wild type CBL were detected, we concluded
that the patient harbors a compound heterozygous progenitor
clone with distinct mutations of both CBL alleles (Figure 3B).
Mechanisms that increase mutant CBL dosage
Our data on CBL suggest that there are several different
genetic mechanisms for how the malignant clone can increase
the mutant CBL allele dosage (Figure 3C). The first mechanism
is via mitotic recombination resulting in UPD. The second
mechanism is the mutant allele by duplication. Another
possibility is the inactivation of wild type alleles by two
independent point mutations (compound heterozygosity).
Interestingly, it seems possible that loss of a single CBL allele
(haploinsufficiency) might be oncogenic as 7 patients in our
cohort carried hemizygous CBL deletions (Figure 2). In support
of this hypothesis, heterozygous Cbl deficiency in mice showed
Figure 2.  Summary of chromosome 11 aberrations.  Large chromosomal aberrations are indicated with colored bars around the
ideogram of chromosome 11. Green – gains; red – deletions; blue – uniparental disomies. The position of the bars relative to the
chromosome ideogram indicates the position and size of the aberration. For the two patients of whom two samples were analyzed
(UPN 23 and UPN 42 – see Table S1) recurrent aberrations are depicted only once. The positions of CBL, MLL, EED, SF1, DDB1
and LMO2 are indicated by vertical lines. Mutations in these genes are depicted by orange circles along these lines. Common
deleted regions are indicated at the bottom of Figure 2 listing the genes they cover. The ideogram depicts G-banding pattern at
~850-band resolution level.
doi: 10.1371/journal.pone.0077819.g002
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accelerated blast crisis compared to Cbl wild type animals in a
BCR-ABL transgenic murine model [27]. In addition,
hemizygous deletions of CBL have been shown by others in
MDS and related disorders [33].
Mutation of DDB1 associated with 11q UPD
Recently, mutations in the splicing factor 1 gene SF1
(ensembl gene ID: ENSG00000168066) and a member of the
polycomb complex 2 (EED – ensembl gene ID:
ENSG00000074266) were found in myeloid malignancies
[34,35]. Both genes are located on chromosome 11q (Figure
2). We did not find any mutations in these two genes by either
whole exome or Sanger sequencing of EED and the C-terminal
Figure 3.  Mutational patterns in CBL.  A: Sample 45 had a 6 bp tandem duplication in CBL leading to the insertion of the amino
acids valine (V) and aspartic acid (D) after position 390. B: One sample identified in a cohort screen for mutations in CBL exons 8
and 9 carried two mutations, one in exon 8 (W408C) and a second one in intron 8 at the splice acceptor site (G to A). PCR
subcloning and analysis of colony DNA revealed that the two mutations are on different alleles. Depicted are two representative
colonies. Colony 43 has the mutation in exon 8 but not in intron 8 whereas colony 17 shows the opposite case. A, B: Depicted are
the genomic (letters) as well as the respective amino acid (box chains) sequences. Numbers indicate amino acid positions in the Cbl
protein. Amino acids, which are substituted due to mutations are in red boxes. The splice site alteration is a red circle. Black arrows
indicate the positions of the mutations below the Sanger sequencing traces. C: Overview of CBL mutagenesis in MPN. Different
genetic mechanisms are involved in increasing mutant gene dosage of CBL. Each panel shows schematically the two parental
copies of chromosomes 11 (blue and yellow) and the CBL gene (white rectangles). Mutations are indicated with asterisks. From left
to right: heterozygous mutation in CBL; uniparental disomy introduces homozygous CBL mutations; gain of a part of chromosome
11q leads to a duplication of the CBL mutation while one wild type allele is still present; compound heterozygosity established by
two different mutations on the different alleles of the CBL gene in one cell. In addition, the loss of a part of chromosome 11q deleting
one CBL allele and leaving the other allele unaffected (wild type CBL) is likely to introduce phenotypes due to haploinsufficiency.
doi: 10.1371/journal.pone.0077819.g003
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proline-rich region of SF1 that was found to be the mutational
hotspot of the gene [34]. All samples that had aberrations
spanning the two loci were analyzed (Figure 2). We performed
whole exome sequencing of samples 30, 36, 42, 43 and 50 and
attempted to identify genes other than CBL that might be
associated with aberrations of chromosome 11q (Table S2). In
two of the patients (samples 30 and 36), we performed a paired
analysis as whole exome sequenced T lymphocyte DNA was
available as germline control (samples 30c and 36c). In sample
30 we did not find any somatic mutations with an allelic
frequency > 50%, which is expected for variants within the fully
clonal 11qUPD region (data not shown). In addition to the
somatic mutation in CBL described above, sample 36 also
harbored another somatic mutation in DDB1 (ensembl gene ID:
ENSG00000167986) (Figure 4A). The CBL and DDB1
mutations in sample 36 were validated by Sanger sequencing
and shown to be homozygous and fully clonal (Figure 4A). Both
mutations were also detected in an earlier sample of the same
patient (sample 23). Sample 23 harbored an 11qUPD in a
subclone and accordingly, the mutations in CBL and DDB1
were not fully clonal (data not shown). The Polyphen2 tool
used to predict functional effects of human non-synonymous
single nucleotide variants estimated the variant in DDB1 to be
“probably damaging” with the highest probability score of 1.
DDB1 was originally identified in patients suffering from
Xeroderma pigmentosum, with inherited deficiency in
nucleotide excision repair (NER). The gene was cloned
together with its binding partner DDB2, with which it forms the
DDB protein complex [36]. Later, DDB1 was found to form an
E3 ubiquitin ligase complex together with CUL4A, ROC1 and a
variable fourth protein that determines the target specificity of
the E3 ligase. Overall, more than 30 different proteins have
been identified as binding partners [37]. The ubiquitination
activity of DDB1-CUL4A-ROC1 complexes has been shown to
not only play important roles in NER [38] but also in regulating
the expression of the tumor suppressor CDKN2A [39].
CDKN2A gene expression is associated with histone 3 – lysine
4 (H3K4) trimethylation mediated by the MLL-RBBP5-WDR5
complex. RBBP5 and WDR5 are two of the binding partners of
the DDB1-CUL4A-ROC1 complex. DDB1 expression is
required, together with MLL, for proper CDKN2A transcriptional
activation [39]. Thus, inactivating mutations of DDB1 are likely
to contribute to cancer not only by impairing NER, but also by
preventing the transcription of tumor suppressor genes. It
remains to be seen if the described example of a concerted
action of DDB1 and MLL is unique or if there is a systematic
relationship between these two genes that might play a role in
hematologic malignancies.
In the remaining three samples that were whole exome
sequenced (samples 42, 43 and 50) we identified a number of
SNVs and small indels that we could validate by Sanger
sequencing (Table S3). Only one gene appeared to be
recurrent in this dataset, HEPHL1. Two patients (samples 42
and 50) harbored both an SNV in the HEPHL1 gene as
indicated in Table S3. The function of HEPHL1 is not known.
As we did not have control tissue available from these patients,
we were unable to identify the somatic or germline origin of
these variants.
Tandem duplication in exon 3 of MLL associated with
11q UPD
In order to find small scale genetic alterations that are either
too small to be detected by Affymetrix microarrays or too large
to be detected by standard exome sequencing pipelines, we
analyzed exome coverage data that we gained after alignment
of the short sequence reads to the human reference genome.
We compared the coverage data of each of the five exome
datasets to a set of control samples to identify regions of focal
deletions or gains on chromosome 11q. In sample 50, we were
able to detect a focal amplification in exon 3 of MLL (ensembl
gene ID: ENSG00000118058) (Figure 4B). Independent
analysis by Sanger sequencing revealed a 513 bp tandem
duplication in MLL exon 3. This duplication translates to an in-
frame duplication of 171 amino acids from position 528 to 698
of the MLL protein (uniprot ID Q03164-1) (Figure 4B). We did
not have control tissue of this patient available to confirm the
somatic origin of this duplication. However, the duplication was
not present in 196 control subjects ruling out the possibility of a
common germline polymorphism. Tandem duplications in MLL
have been described but usually affect the region from exon 3
to exon 9, 10 or 11 [8]. Small tandem duplications such as the
513 bp within exon 3 detected in our study have not been
reported so far.
Chromosome 11p defects associate with de novo AML
or target LMO2
On chromosome 11p, we identified a total of 4 CDRs (Figure
2). The most telomeric CDR contained 14 genes. Interestingly,
we found a significant association of aberrations spanning this
CDR with de novo AML compared to secondary AML (P =
0.013). It is likely that one or more of the genes in this region
play a particular role in de novo AML pathogenesis. The most
centromeric CDR on the short arm of chromosome 11, defined
by a deletion in sample 39 contains the LMO2 gene (ensembl
gene ID: ENSG00000135363). In sample 32, where we
detected a deletion spanning the LMO2 locus (Table S1), we
also found an SNV in LMO2 in the remaining allele (c.G388A;
p. G130S, Uniprot ID P25791-3) that was hemizygous in
Sanger sequencing traces (Figure 4C). The Polyphen2 tool
estimated the variant to be “probably damaging” with the
highest probability score of 1. Due to lack of control tissue in
this patient we could not analyze the somatic or germline origin
of this SNV. Based on the available data we postulate that
there is a full loss of LMO2 activity in this patient. We tested all
other patients with aberrations overlapping the LMO2 locus, but
were unable to find any mutations in the coding region or at
splice sites of LMO2 (data not shown). The deletions were
detected across several different pathologies. LMO2 is
frequently involved in translocations in T-cell leukemia [40]. It is
expressed in different fetal tissues [41] and the full knockout in
the mouse is known to be embryonic lethal [42]. Warren et al.
showed that LMO2 is essential for erythroid development in the
mouse. Deficiency in erythropoiesis was detected at E9.75.
They confirmed by in vitro differentiation assays that this defect
is intrinsic to the hematopoietic system and specific for the
erythroid lineage [42]. Interestingly the patient in our study
Genetics of Chromosome 11 in Myeloid Malignancies
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showed anemia with an hemoglobin level of 97 g/L at the time
of sampling.
Concluding remarks and perspectives
In this study we applied a chromosome centered genetic
analysis of myeloid malignancies. The rationale of this
approach is that those chromosomes that exhibit frequent
chromosomal defects might also harbor point mutations in the
target genes of deletions, gains or UPD. Combining SNP
microarray analysis and exome sequencing may increase the
likelihood of identification of novel tumor suppressor genes or
oncogenes. Applying this approach we systematically analyzed
Figure 4.  Mutations detected in DDB1, MLL and LMO2.  A: Sample 36 harbored an 11q UPD as indicated by the blue bar below
the chromosome 11 ideogram. We found two somatic mutations in DDB1 and CBL. As can be seen in the Sanger sequencing
traces, both mutations are homozygous due to amplification by the UPD. B: In sample 50 a tandem duplication in MLL exon 3 was
detected. The top graph shows whole exome coverage data across MLL exon 3. The data is plotted as the log2 ratio of the
normalized exome sequencing coverage in the patient sample divided by the median normalized coverage of 8 independent control
samples at each genomic position (X-axis). The position of the duplication is indicated by the red bar. Sanger sequencing confirmed
an in-frame tandem duplication of 171 amino acids as shown at the bottom. C: A common deleted region on chromosome 11p
targets LMO2. All deletions in the analyzed cohort that span the LMO2 locus are depicted next to the chromosome 11 ideogram.
Red bars indicate deletions, green bars indicate gains. In sample 42, which harbored a deletion spanning the LMO2 locus, we also
detected a point mutation in LMO2. The middle section shows a signal intensity plot measuring copy number from Affymetrix
microarrays. The plot depicts signal intensity (log2 scale) differences between the patient and a healthy control pool for each probe
(as implemented in the Affymetrix Genotyping Console software). The deletion in sample 42 can be seen as the deviation from 0 for
all probes in the deleted genomic region (X-axis). The point mutation in LMO2 as identified by Sanger sequencing is depicted at the
bottom of panel C. A, B and C: Depicted are the genomic (letters) as well as the respective amino acid (box chains) sequences.
Numbers above the boxes indicate amino acid positions in the proteins. Amino acids substituted in the patient samples are indicated
by red boxes. The red circle indicates a splice site mutation. Reference and mutant sequences are shown. The arrows indicate the
site of mutations below the Sanger sequencing traces.
doi: 10.1371/journal.pone.0077819.g004
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chromosome 11 in myeloid malignancies and detected a large
complexity of genetic aberrations especially in patients with
AML (de novo or secondary to MPN and MDS). The various
genetic lesions of chromosome 11 in myeloid malignancies
target CBL, MLL, DDB1, LMO2 and possibly other tumor
suppressor genes that we could not identify in this study. The
marked cytogenetic complexity associated with AML points
towards a highly individual course of disease progression in
each patient and might explain the current difficulty in treating
patients that have transformed to AML.
Our data indicates that genetic stratification of patients into
comparable groups at advanced disease stage will be
extremely challenging or impossible due to highly individual
mutagenesis profiles. Despite individual mutagenesis profiles, it
is possible that common molecular features may emerge
(based on gene expression and/or protein phosphorylation
profiles). Systems level approaches may help in overcoming
this obstacle of genetic heterogeneity, opening up the
possibility of targeted therapies in the future. Based on current
knowledge, treatment efforts in the chronic phase of myeloid
malignancies should not only focus on correction of blood
counts but also focus on prevention of disease progression as
therapeutic intervention in advance disease stages are
predicted to be difficult as the genetic complexity of tumors
reach an immense scale.
Materials and Methods
Ethics statement
Peripheral blood samples were collected from patients after
written informed consent. Sample collection was approved by
local ethics committees. These were the “Ethik Kommission der
Medizinischen Universität Wien” for samples collected in
Austria, the “Comitato di Bioetica” for samples collected at the
Fondazione Istituto di Ricovero e Cura a Carattere Scientifico
(IRCCS) Policlinico San Matteo, Pavia, Italy, the “Local Ethical
Committee of Azienda Ospedaliera-Universitaria Careggi,
Firenze” for samples collected at the University of Florence,
Italy, the Ethics Committee of University Hospital Brno for
samples collected at the Masaryk University Brno, Czech
Republic, and the ”Eticki odbor Klinickog centra Srbije” for
samples collected at the University of Belgrade, Serbia.
Patient samples
We analyzed a total of 813 samples from 773 patients. For
40 patients we had two samples available, which were in all
cases from two different disease stages. Detailed information
on the studied cohort is provided in Table 1. Genomic DNA
was isolated from whole blood, granulocytes or mononuclear
cell fractions according to standard procedures. For a subset of
patients we had control tissue DNA available, extracted from
either buccal mucosa cells, T lymphocyte fractions of
peripheral blood or cultured skin fibroblasts.
Microarray analysis and whole exome sequencing
The genomic DNA was processed and hybridized to
Genome-Wide Human SNP 6.0 arrays (Affymetrix, Santa
Clara, CA) according to the manufacturer’s instructions.
Chromosomal copy number changes and UPDs were detected
using the Genotyping Console version 3.0.2 software
(Affymetrix).
Five tumor samples (30, 36, 42, 43 and 50) and two matched
control samples (30c and 36c) were analyzed by whole exome
sequencing (Table S1). Genomic DNA libraries were generated
either by using the NEBNext DNA Sample Prep Reagent Set 1
(New England Biolabs, Ipswich, MA) for sample 30 or the
TruSeq DNA Sample Prep-Kit v2 (Illumina, San Diego, CA) for
samples 36, 42, 43, 50, 30c and 36c. Whole exome enrichment
was performed using the Sure Select Human All Exon Kit
(Agilent, Santa Clara, CA) for sample 30 or the TruSeq Exome
Enrichment Kit (Illumina) for the six other samples. The exome
- enriched libraries were hybridized to Illumina flowcells V1
(sample 30) or V3 (other samples) and sequenced using the
Illumina HiSeq 2000 instrument. A summary of all samples and
sequencing parameters is provided in Table S2. The sequence
reads were aligned against the human reference genome
(hg18) using BWA v0.5.9 [43]. Subsequently, the aligned
samples were post processed using GATK v1.5 [44] following
their best practices guidelines (v3). Briefly, this comprises
marking PCR-duplicate reads, recalibrating the base quality
scores and local realignment around insertions/deletions
(indels). Variant discovery was performed on the post-
processed alignment files using GATK’s Unified Genotyper
[45]. The final variant lists were generated using GATK’s
Variant Quality Score Recalibrator using the suggested filtering
parameters.
For samples 30 and 36 where control tissue DNA was whole
exome sequenced (samples 30c and 36c) we performed an
analysis for somatic mutations by using the VarScan2 software
with default parameters[46] starting from the post – processed
alignment files generated by GATK.
For samples 42, 43 and 50 the final variant lists of the GATK
Unified Genotyper were filtered for single nucleotide variants
(SNVs) and indels on chromosome 11 that were passing filter
criteria according to the GATK best practice guidelines v3 and
that were not annotated in dbSNP137. Gene annotation was
done using the ANNOVAR tool version 2012-02-23 [47].
The raw data of microarray analysis and whole exome
sequencing are deposited in the ArrayExpress database under
the accession numbers E-MTAB-1845 and E-MTAB-1850,
respectively.
Coverage analysis from whole exome sequencing data
The analysis was performed for the five tumor samples,
which had been whole exome sequenced. Samtools 0.1.18 [48]
was used with the “depth” option to retrieve coverage data for
chromosome 11 from the post – processed alignment files
generated by the GATK analysis pipeline. The coverage for
each base on chromosome 11 in a particular patient was
normalized by the summarized coverage of all bases of
chromosome 11 in that particular patient. The normalized
coverage of sample 30 was compared to the median
normalized coverage of a set of 5 independent control samples
that had been processed and whole exome sequenced with
similar chemistry and instrumentation as sample 30. A similar
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adequate control set of 8 independent control samples was
generated for samples 36, 42, 43 and 50. All of the control
samples used showed wild-type chromosome 11 as analyzed
by Genome-Wide Human SNP 6.0 arrays (Affymetrix, data not
shown).
PCR, Sanger sequencing, PCR subcloning
Primers for PCR were designed using the Primer 3 tool
(http://www.bioinformatics.nl/cgi-bin/primer3plus/
primer3plus.cgi) or the ExonPrimer tool (http://ihg.gsf.de/ihg/
ExonPrimer.html) except for the primers amplifying CBL exons
8 and 9 which were taken from a publication by Sanada et al
[27]. Primer sequences and PCR conditions are listed in Table
S4. PCRs were performed using the AmpliTaq Gold DNA
Polymerase with Gold Buffer and MgCl2 solution (Applied
Biosystems / Life Technologies, Paisley, UK) or the AmpliTaq
Gold 360 Mastermix (Applied Biosystems). Sanger sequencing
was performed using the BigDye Terminator v3.1 Cycle
Sequencing kit and the 3130xl Genomic Analyzer (Applied
Biosystems). Sequence analysis was done using the
Sequencher Software 4.9 (Gene Codes, Ann Arbor, MI). For
PCR product subcloning the TOPO Cloning Kit (Invitrogen /
Life Technologies, Paisley, UK) was used according to
manufacturer’s instructions. PCR products derived from single
bacterial clones were sequenced as described above.
Statistical analysis and plots
Fisher’s exact tests were performed using Graphpad
QuickCalcs (www.graphpad.com/quickcalcs). The plots
depicting cohort distributions in Figure 1 were done using R
version 2.8.1 (2008-12-22) [49]. The coverage plot in Figure 4B
and the signal intensity plot in Figure 4C were done using
GraphPad Prism version 5.0d for Mac OS X, GraphPad
Software (San Diego, CA), www.graphpad.com.
Supporting Information
Table S1.  List of genetic aberrations on chromosome 11
detected in 52 samples with myeloid malignancies.
(XLS)
Table S2.  Whole exome sequencing parameters.
(XLS)
Table S3.  Validated whole exome sequencing results
overlapping chromosome 11q aberrations.
(XLS)
Table S4.  PCR primers and program.
(XLS)
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